Avacta Group (LON:AVCT) Stock Price Down 4.9% – Here’s Why

Shares of Avacta Group Plc (LON:AVCT) dropped 4.9% on Monday . The company traded as low as GBX 54 and last traded at GBX 58.50. Approximately 2,897,135 shares traded hands during mid-day trading, an increase of 93% from the average daily volume of 1,497,576 shares. The stock had previously closed at GBX 61.50.

Analyst Ratings Changes

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 99 target price on shares of Avacta Group in a research report on Monday, October 13th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of GBX 99.

Avacta Group Price Performance

The firm has a fifty day moving average of GBX 70.43 and a 200 day moving average of GBX 58.46. The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53. The company has a market capitalization of £253.69 million, a P/E ratio of -3.33 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).